Note 1 - Basis of Presentation and Summary of Significant Accounting Policies
|9 Months Ended|
Mar. 31, 2015
|Notes to Financial Statements|
|Business Description and Accounting Policies [Text Block]||
and Summary of Significant Accounting Policies
The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2014, included in the Company’s Annual Report on Form 10-K for fiscal 2014. A summary of significant accounting policies followed by the Company is detailed in the Company’s Annual Report on Form 10-K for fiscal 2014. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements.
The Company’s available-for-sale securities are carried at fair value using Level 1 and Level 2 inputs. The fair value of the Company’s available-for-sale investments at March 31, 2015 and June 30, 2014 were $53.5 million and $48.4 million, respectively. The amortized cost basis of the Company’s available-for-sale investments at March 31, 2015 and June 30, 2014 were $35.0 million and $40.7 million, respectively.
Included in the Company’s available-for-sale securities is an investment in the common stock and warrants of ChemoCentryx Inc. CCXI. The fair value of the Company’s investment was $48.0 million and $37.1 million at March 31, 2015 and June 30, 2014, respectively. The cost basis of the Company’s investment in CCXI was $29.5 million at both March 31, 2015 and June 30, 2014.
Inventories consist of (in thousands):
At March 31, 2015 and June 30, 2014, the Company had approximately $24 million and $30 million of excess protein, antibody and chemically-based inventory on hand which was not valued, respectively. The decline in the reserve balance is the result of the company disposing of excess inventory.
Property and Equipment:
Property and equipment consist of (in thousands):
Intangible assets consist of (in thousands):
Changes to the carrying amount of net intangible assets for the nine months ended March 31, 2015 consist of (in thousands):
The estimated future amortization expense for intangible assets as of March 31, 2015 is as follows (in thousands):
Changes to the carrying amount of goodwill for the nine months ended March 31, 2015 consist of (in thousands):
The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
No definition available.